Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.04
-0.72-3.47%
At close: -
$20.04
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Tandem Diabetes Care Analyst Ratings and Price Targets | NASDAQ:TNDM | Benzinga
Tandem Diabetes Care Inc has a consensus price target of $41.24 based on the ratings of 28 analysts. The high is $82 issued by Wells Fargo on August 4, 2022. The low is $20 issued by Wells Fargo on May 1, 2025. The 3 most-recent analyst ratings were released by Truist Securities, Citigroup, and Canaccord Genuity on June 16, 2025, May 22, 2025, and May 1, 2025, respectively. With an average price target of $35.67 between Truist Securities, Citigroup, and Canaccord Genuity, there's an implied 77.98% upside for Tandem Diabetes Care Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Citigroup
Canaccord Genuity
Stifel
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Tandem Diabetes Care
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/16/2025 | Buy Now | 19.76% | Truist Securities | Richard Newitter73% | → $24 | Initiates | → Hold | Get Alert |
| 05/22/2025 | Buy Now | 19.76% | Citigroup | Joanne Wuensch74% | $20 → $24 | Maintains | Neutral | Get Alert |
| 05/01/2025 | Buy Now | 194.41% | Canaccord Genuity | William Plovanic59% | $58 → $59 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | 54.69% | Stifel | Mathew Blackman61% | $60 → $31 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | -0.2% | Wells Fargo | Larry Biegelsen66% | $22 → $20 | Maintains | Equal-Weight | Get Alert |
| 05/01/2025 | Buy Now | 49.7% | Piper Sandler | Matt O'Brien53% | $36 → $30 | Maintains | Overweight | Get Alert |
| 05/01/2025 | Buy Now | 19.76% | Baird | Jeff Johnson76% | $33 → $24 | Maintains | Neutral | Get Alert |
| 04/10/2025 | Buy Now | -0.2% | Mizuho | Anthony Petrone64% | → $20 | Initiates | → Neutral | Get Alert |
| 03/05/2025 | Buy Now | 9.78% | Morgan Stanley | Patrick Wood48% | $45 → $22 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/04/2025 | Buy Now | 19.76% | Citigroup | Joanne Wuensch74% | $35 → $24 | Downgrade | Buy → Neutral | Get Alert |
| 03/03/2025 | Buy Now | 19.76% | Goldman Sachs | David Roman41% | $42 → $24 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 9.78% | Wells Fargo | Larry Biegelsen66% | $38 → $22 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/28/2025 | Buy Now | 164.47% | Barclays | Matt Miksic66% | $60 → $53 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 174.45% | RBC Capital | Shagun Singh57% | $65 → $55 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 64.67% | Baird | Jeff Johnson76% | $37 → $33 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | 214.37% | Canaccord Genuity | William Plovanic59% | $63 → $63 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 149.5% | Citigroup | Joanne Wuensch74% | $57 → $50 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 124.55% | Morgan Stanley | Patrick Wood48% | $45 → $45 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/08/2024 | Buy Now | 199.4% | Barclays | Matt Miksic66% | $58 → $60 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 179.44% | Canaccord Genuity | William Plovanic59% | $57 → $56 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 84.63% | Baird | Jeff Johnson76% | $39 → $37 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | 109.58% | Bernstein | Lee Hambright69% | → $42 | Initiates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 129.54% | Goldman Sachs | David Roman41% | → $46 | Initiates | → Neutral | Get Alert |
| 10/02/2024 | Buy Now | 224.35% | RBC Capital | Shagun Singh57% | → $65 | Initiates | → Outperform | Get Alert |
| 09/23/2024 | Buy Now | 124.55% | Morgan Stanley | Patrick Wood48% | $45 → $45 | Maintains | Equal-Weight | Get Alert |
| 08/22/2024 | Buy Now | 124.55% | Morgan Stanley | Patrick Wood48% | → $45 | Initiates | → Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 184.43% | Canaccord Genuity | William Plovanic59% | → $57 | Initiates | → Buy | Get Alert |
| 08/05/2024 | Buy Now | 189.42% | Barclays | Matt Miksic66% | $55 → $58 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 174.45% | Wells Fargo | Larry Biegelsen66% | $50 → $55 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 94.61% | Baird | Jeff Johnson76% | $36 → $39 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 174.45% | Piper Sandler | Matt O'Brien53% | $50 → $55 | Reiterates | Overweight → Overweight | Get Alert |
| 06/10/2024 | Buy Now | 189.42% | Oppenheimer | Steven Lichtman62% | $47 → $58 | Maintains | Outperform | Get Alert |
| 05/30/2024 | Buy Now | 199.4% | Redburn Atlantic | Issie Kirby30% | → $60 | Initiates | → Buy | Get Alert |
| 05/29/2024 | Buy Now | 199.4% | Stifel | Mathew Blackman61% | $55 → $60 | Maintains | Buy | Get Alert |
| 05/22/2024 | Buy Now | 274.25% | Lake Street | Brooks O'Neil35% | $60 → $75 | Maintains | Buy | Get Alert |
| 05/22/2024 | Buy Now | 184.43% | Citigroup | Joanne Wuensch74% | $40 → $57 | Upgrade | Neutral → Buy | Get Alert |
| 05/22/2024 | Buy Now | 174.45% | Stifel | Mathew Blackman61% | $45 → $55 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 174.45% | Barclays | Matt Miksic66% | $39 → $55 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 124.55% | Stifel | Mathew Blackman61% | $40 → $45 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 149.5% | Wells Fargo | Larry Biegelsen66% | $45 → $50 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 149.5% | Piper Sandler | Matt O'Brien53% | $35 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 79.64% | Baird | Jeff Johnson76% | $28 → $36 | Maintains | Neutral | Get Alert |
| 04/29/2024 | Buy Now | 124.55% | Wells Fargo | Larry Biegelsen66% | $21 → $45 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/25/2024 | Buy Now | 124.55% | Leerink Partners | Mike Kratky66% | $34 → $45 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/23/2024 | Buy Now | 99.6% | Stifel | Mathew Blackman61% | $37 → $40 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 89.62% | Citigroup | Joanne Wuensch74% | $31 → $38 | Maintains | Neutral | Get Alert |
| 03/26/2024 | Buy Now | 84.63% | Stifel | Mathew Blackman61% | $24 → $37 | Upgrade | Hold → Buy | Get Alert |
| 03/15/2024 | Buy Now | 54.69% | Citigroup | Joanne Wuensch74% | $25 → $31 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 19.76% | Stifel | Rick Wise73% | $17 → $24 | Maintains | Hold | Get Alert |
| 11/02/2023 | Buy Now | 24.75% | Piper Sandler | Matt O'Brien53% | $40 → $25 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | 4.79% | Leerink Partners | Mike Kratky66% | → $21 | Initiates | → Market Perform | Get Alert |
| 10/02/2023 | Buy Now | 14.77% | Citigroup | Joanne Wuensch74% | $31 → $23 | Maintains | Neutral | Get Alert |
| 10/02/2023 | Buy Now | 124.55% | Jefferies | Matthew Taylor69% | $47 → $45 | Maintains | Buy | Get Alert |
| 08/21/2023 | Buy Now | 54.69% | Citigroup | Joanne Wuensch74% | $33 → $31 | Maintains | Neutral | Get Alert |
| 08/21/2023 | Buy Now | 59.68% | Baird | Jeff Johnson76% | $33 → $32 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 209.38% | Barclays | Matt Miksic66% | $71 → $62 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 69.66% | TD Cowen | Joshua Jennings57% | $52 → $34 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 49.7% | Wells Fargo | Larry Biegelsen66% | $40 → $30 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 64.67% | Baird | Jeff Johnson76% | $38 → $33 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 64.67% | Citigroup | Joanne Wuensch74% | $45 → $33 | Downgrade | Buy → Neutral | Get Alert |
| 06/13/2023 | Buy Now | 149.5% | Craig-Hallum | Alexander Nowak53% | $74 → $50 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 124.55% | Citigroup | Joanne Wuensch74% | $55 → $45 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 64.67% | B of A Securities | Travis Steed57% | $45 → $33 | Downgrade | Neutral → Underperform | Get Alert |
| 05/04/2023 | Buy Now | 99.6% | Wells Fargo | Larry Biegelsen66% | $43 → $40 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 89.62% | Baird | Jeff Johnson76% | $40 → $38 | Maintains | Neutral | Get Alert |
| 04/24/2023 | Buy Now | — | Raymond James | Jayson Bedford67% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/29/2023 | Buy Now | 124.55% | UBS | Danielle Antalffy61% | → $45 | Initiates | → Neutral | Get Alert |
| 02/24/2023 | Buy Now | 134.53% | Raymond James | Jayson Bedford67% | $52 → $47 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 159.48% | Cowen & Co. | Joshua Jennings57% | $61 → $52 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 99.6% | Baird | Jeff Johnson76% | $45 → $40 | Maintains | Neutral | Get Alert |
| 02/23/2023 | Buy Now | 149.5% | Piper Sandler | Matt O'Brien53% | $70 → $50 | Maintains | Overweight | Get Alert |
| 01/26/2023 | Buy Now | — | Wolfe Research | Mike Polark55% | — | Initiates | → Peer Perform | Get Alert |
| 11/15/2022 | Buy Now | 114.57% | Wells Fargo | Larry Biegelsen66% | → $43 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | 159.48% | Raymond James | Jayson Bedford67% | $92 → $52 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 249.3% | Piper Sandler | Matt O'Brien53% | $80 → $70 | Maintains | Overweight | Get Alert |
| 10/18/2022 | Buy Now | 274.25% | Barclays | Matt Miksic66% | → $75 | Initiates | → Overweight | Get Alert |
| 10/12/2022 | Buy Now | 274.25% | Jefferies | Matthew Taylor69% | → $75 | Initiates | → Buy | Get Alert |
| 09/07/2022 | Buy Now | — | OTR Global | — | — | Downgrade | Positive → Mixed | Get Alert |
| 08/09/2022 | Buy Now | 144.51% | Wells Fargo | Larry Biegelsen66% | $82 → $49 | Downgrade | Overweight → Underweight | Get Alert |
| 08/04/2022 | Buy Now | 349.1% | Raymond James | Jayson Bedford67% | $125 → $90 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 309.18% | Wells Fargo | Lawrence Biegelsen48% | $166 → $82 | Maintains | Overweight | Get Alert |
| 08/04/2022 | Buy Now | 299.2% | Piper Sandler | Matt O'Brien53% | $120 → $80 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Tandem Diabetes Care (TNDM) stock?
The latest price target for Tandem Diabetes Care (NASDAQ:TNDM) was reported by Truist Securities on June 16, 2025. The analyst firm set a price target for $24.00 expecting TNDM to rise to within 12 months (a possible 19.76% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tandem Diabetes Care (TNDM)?
The latest analyst rating for Tandem Diabetes Care (NASDAQ:TNDM) was provided by Truist Securities, and Tandem Diabetes Care initiated their hold rating.
When was the last upgrade for Tandem Diabetes Care (TNDM)?
The last upgrade for Tandem Diabetes Care Inc happened on December 2, 2024 when Morgan Stanley raised their price target to $45. Morgan Stanley previously had an equal-weight for Tandem Diabetes Care Inc.
When was the last downgrade for Tandem Diabetes Care (TNDM)?
The last downgrade for Tandem Diabetes Care Inc happened on March 5, 2025 when Morgan Stanley changed their price target from $45 to $22 for Tandem Diabetes Care Inc.
When is the next analyst rating going to be posted or updated for Tandem Diabetes Care (TNDM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tandem Diabetes Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tandem Diabetes Care was filed on June 16, 2025 so you should expect the next rating to be made available sometime around June 16, 2026.
Is the Analyst Rating Tandem Diabetes Care (TNDM) correct?
While ratings are subjective and will change, the latest Tandem Diabetes Care (TNDM) rating was a initiated with a price target of $0.00 to $24.00. The current price Tandem Diabetes Care (TNDM) is trading at is $20.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
